- Home
- CVRX vs FDMT Comparison
CVRX vs FDMT Comparison
Compare CVRX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVRX
- FDMT
- Stock Information
- Founded
- CVRX 2000
- FDMT 2013
- Country
- CVRX United States
- FDMT United States
- Employees
- CVRX N/A
- FDMT N/A
- Industry
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- CVRX Health Care
- FDMT Health Care
- Exchange
- CVRX Nasdaq
- FDMT Nasdaq
- Market Cap
- CVRX 174.4M
- FDMT 192.2M
- IPO Year
- CVRX 2021
- FDMT 2020
- Fundamental
- Price
- CVRX $6.86
- FDMT $4.32
- Analyst Decision
- CVRX Buy
- FDMT Buy
- Analyst Count
- CVRX 7
- FDMT 10
- Target Price
- CVRX $14.50
- FDMT $32.33
- AVG Volume (30 Days)
- CVRX 171.6K
- FDMT 436.5K
- Earning Date
- CVRX 07-28-2025
- FDMT 08-07-2025
- Dividend Yield
- CVRX N/A
- FDMT N/A
- EPS Growth
- CVRX N/A
- FDMT N/A
- EPS
- CVRX N/A
- FDMT N/A
- Revenue
- CVRX $52,870,000.00
- FDMT $23,000.00
- Revenue This Year
- CVRX $11.53
- FDMT $13,048.65
- Revenue Next Year
- CVRX $18.61
- FDMT N/A
- P/E Ratio
- CVRX N/A
- FDMT N/A
- Revenue Growth
- CVRX 25.62
- FDMT N/A
- 52 Week Low
- CVRX $4.30
- FDMT $2.24
- 52 Week High
- CVRX $18.55
- FDMT $28.93
- Technical
- Relative Strength Index (RSI)
- CVRX 61.51
- FDMT 57.43
- Support Level
- CVRX $6.30
- FDMT $3.86
- Resistance Level
- CVRX $7.21
- FDMT $4.48
- Average True Range (ATR)
- CVRX 0.35
- FDMT 0.28
- MACD
- CVRX 0.16
- FDMT 0.01
- Stochastic Oscillator
- CVRX 83.24
- FDMT 89.81
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.